Logo-ijhpm
Int J Health Policy Manag. 2019;8(10): 575-582. doi: 10.15171/ijhpm.2019.36
PMID: 31657184        PMCID: PMC6819627

Original Article

Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling

Janneke P.C. Grutters 1 * ORCID, Tim Govers 2 ORCID, Jorte Nijboer Nijboer 2, Marcia Tummers 1 ORCID, Gert Jan van der Wilt 3 ORCID, Maroeska M. Rovers 4

Cited by CrossRef:

1- Scholte M, Rovers M, Grutters J. The Use of Decision Analytic Modeling in the Evaluation of Surgical Innovations: A Scoping Review. Value in Health. 2021;24(6):884 [Crossref]
2- Scholte M, Marchau V, Kwakkel J, Klijn C, Rovers M, Grutters J. Dealing With Uncertainty in Early Health Technology Assessment: An Exploration of Methods for Decision Making Under Deep Uncertainty. Value in Health. 2023;26(5):694 [Crossref]
3- Langius-Wiffen E, de Jong P, Hoesein F, Dekker L, van den Hoven A, Nijholt I, Boomsma M, Veldhuis W. Retrospective batch analysis to evaluate the diagnostic accuracy of a clinically deployed AI algorithm for the detection of acute pulmonary embolism on CTPA. Insights Imaging. 2023;14(1) [Crossref]
4- Tummers M, Kværner K, Sampietro-Colom L, Siebert M, Krahn M, Melien Ø, Hamerlijnck D, Abrishami P, Grutters J. On the integration of early health technology assessment in the innovation process: reflections from five stakeholders. Int J Technol Assess Health Care. 2020;36(5):481 [Crossref]
5- Vreman R, Geenen J, Knies S, Mantel-Teeuwisse A, Leufkens H, Goettsch W. The Application and Implications of Novel Deterministic Sensitivity Analysis Methods. PharmacoEconomics. 2021;39(1):1 [Crossref]
6- Verbeek J, van der Sluis K, Vollebergh M, van Sandick J, van Harten W, Retèl V. Early Cost-Effectiveness Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients with Limited Peritoneal Carcinomatosis. PharmacoEconomics Open. 2024;8(1):119 [Crossref]
7- Marcus H, Ramirez P, Khan D, Layard Horsfall H, Hanrahan J, Williams S, Beard D, Bhat R, Catchpole K, Cook A, Hutchison K, Martin J, Melvin T, Stoyanov D, Rovers M, Raison N, Dasgupta P, Noonan D, Stocken D, Sturt G, Vanhoestenberghe A, Vasey B, McCulloch P, Chari A, Ficuciello F, Vayena E, Baber C, Zenati M, Kuntz A, Kerr K, Horwood N, Anderon K, Kwok K, Mahoney R, Peine B, Baena F, Valdastri P, Leparmentier R, Evans L, Langley R, Sutherland G, Lama S, Soomro N, Collins J, Leitao M, Kinross J, Goh A, Park B, Weigl M, Randell R, Yule S, McPherson D, Pickup L, Skipworth R, Anger J, Yu D, Cavuoto L, Bisantz A, Cohen T, Scholte M, Maddern G, Sampietro-Colom L, Clark A, Clifford T, Corbacho B, Iglesias C, Grutters J, Hutchinson K, Booth L, Draper H, Evans L, Goering S, Kon A, Langley R, Sparrow R, Ahmed K, Harji D, Grantcharov T, Konge L, Sedrakyan A, Horowitz J, Paez A. The IDEAL framework for surgical robotics: development, comparative evaluation and long-term monitoring. Nat Med. 2024;30(1):61 [Crossref]
8- Pascal C, Mathy C, Bongiovanni I, Konishi M. Integrating organizational impacts into health technology assessment (HTA): an analysis of the content and use of existing evaluation frameworks. Int J Technol Assess Health Care. 2022;38(1) [Crossref]
9- Castelluccia A, Mincarone P, Tumolo M, Sabina S, Colella R, Bodini A, Tramacere F, Portaluri M, Leo C. Economic Evaluations of Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A Systematic Review. IJERPH. 2022;19(17):10800 [Crossref]
10- Federici C, Pecchia L. Exploring the misalignment on the value of further research between payers and manufacturers. A case study on a novel total artificial heart. Health Economics. 2022;31(S1):98 [Crossref]
11- Browne I, Sutton A, Zhang W. Perceptions and Attitudes Regarding Medical Device Development in Canada Among Canadian Innovators: A Qualitative Study. PharmacoEconomics Open. 2023;7(5):793 [Crossref]
12- Vermeulen R, Govers T, van Leeuwen K. Early health technology assessment: the value of valuing AI applications. Eur Radiol. 2024;34(9):5854 [Crossref]
13- Hill‐McManus D, Marshall S, Liu J, Willke R, Hughes D. Linked Pharmacometric‐Pharmacoeconomic Modeling and Simulation in Clinical Drug Development. Clin Pharma and Therapeutics. 2021;110(1):49 [Crossref]
14- Cai Y, Philips E, Arora S, Sim J, Chow W, Nazeha N, Whiteley S, Auw M, Tiang D, Neo S, Hong W, Venkatachalam I, Graves N. Cost-effectiveness of a real-time spatiotemporal mapping surveillance system for meticillin-resistant Staphylococcus aureus prevention. Journal of Hospital Infection. 2024;143:178 [Crossref]
15- Browne I, Zhang W, Sutton A. Exploring the approach to parameter uncertainty in early economic evaluations of surgical technology – a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research. 2023;23(1):29 [Crossref]
16- Bouttell J, Briggs A, Hawkins N. A different animal? Identifying the features of health technology assessment for developers of medical technologies. Int J Technol Assess Health Care. 2020;36(4):285 [Crossref]
17- Simões Corrêa Galendi J, Yeo S, Grüll H, Bratke G, Akuamoa-Boateng D, Baues C, Bos C, Verkooijen H, Shukri A, Stock S, Müller D. Early economic modeling of magnetic resonance image-guided high intensity focused ultrasound compared to radiotherapy for pain palliation of bone metastases. Front Oncol. 2022;12 [Crossref]
18- Langius-Wiffen E, de Jong P, Mohamed Hoesein F, Dekker L, van den Hoven A, Nijholt I, Boomsma M, Veldhuis W. Added value of an artificial intelligence algorithm in reducing the number of missed incidental acute pulmonary embolism in routine portal venous phase chest CT. Eur Radiol. 2023;34(1):367 [Crossref]
19- Kemper E, Erenstein H, Boverhof B, Redekop K, Andreychenko A, Dietzel M, Groot Lipman K, Huisman M, Klontzas M, Vos F, IJzerman M, Starmans M, Visser J. ESR Essentials: how to get to valuable radiology AI: the role of early health technology assessment—practice recommendations by the European Society of Medical Imaging Informatics. Eur Radiol. 2024; [Crossref]
20- Cocco P, Messenger M, Smith A, West R, Shinkins B. Integrating Early Economic Evaluation into Target Product Profile development for medical tests: advantages and potential applications. Int J Technol Assess Health Care. 2021;37(1) [Crossref]
21- Mattock R, Hanbury A, Morys-Edge M, Corp A, Lawton R. An early economic evaluation of WireSafe™ to prevent guidewire retention in central venous catheter procedures. Journal of Patient Safety and Risk Management. 2024;29(6):298 [Crossref]
22- Páez A, Rovers M, Hutchison K, Rogers W, Vasey B, McCulloch P. Beyond the RCT: When are Randomized Trials Unnecessary for New Therapeutic Devices, and What Should We Do Instead?. 2022;275(2):324 [Crossref]
23- Bouttell J, Briggs A, Hawkins N. A toolkit of methods of development-focused health technology assessment. Int J Technol Assess Health Care. 2021;37(1) [Crossref]
24- Bouttell J, Briggs A, Hawkins N. The thorny issue of value alignment: how development-focused health technology assessment can help find win–win situations for patients and healthcare systems and commercial investors. Int J Technol Assess Health Care. 2021;37(1) [Crossref]
25- Hehakaya C, Sharma A, van der Voort Van Zijp J, Grobbee D, Verkooijen H, Izaguirre E, Moors E. Implementation of Magnetic Resonance Imaging-Guided Radiation Therapy in Routine Care: Opportunities and Challenges in the United States. Advances in Radiation Oncology. 2022;7(5):100953 [Crossref]
26- Iskandar R, Federici C, Berns C, Blankart C. An approach to quantify parameter uncertainty in early assessment of novel health technologies. Health Economics. 2022;31(S1):116 [Crossref]
27- Broomhead S, Mars M, Scott R. Appraising eHealth Investment for Africa: Scoping Review and Development of a Framework. IJERPH. 2024;21(10):1277 [Crossref]
28- Zheng K, Kumar S, Sarti A, Herry C, Seely A, Thavorn K. Economic feasibility of a novel tool to assist extubation decision-making: an early health economic modeling. Int J Technol Assess Health Care. 2022;38(1) [Crossref]
29- Doolub G, Mamalakis M, Alabed S, Van der Geest R, Swift A, Rodrigues J, Garg P, Joshi N, Dastidar A. Artificial Intelligence as a Diagnostic Tool in Non-Invasive Imaging in the Assessment of Coronary Artery Disease. Medical Sciences. 2023;11(1):20 [Crossref]
30- Grutters J, Kluytmans A, van der Wilt G, Tummers M. Methods for Early Assessment of the Societal Value of Health Technologies: A Scoping Review and Proposal for Classification. Value in Health. 2022;25(7):1227 [Crossref]
31- Tarricone R, Ciani O, Torbica A, Brouwer W, Chaloutsos G, Drummond M, Martelli N, Persson U, Leidl R, Levin L, Sampietro-Colom L, Taylor R. Lifecycle evidence requirements for high-risk implantable medical devices: a European perspective. Expert Review of Medical Devices. 2020;17(10):993 [Crossref]
32- Handels R, Grimm S, Blokland A, Possemis N, Ramakers I, Sambeth A, Verhey F, Vos S, Joore M, Prickaerts J, Jönsson L. The value of maintaining cognition in patients with mild cognitive impairment: The innovation headroom and potential cost‐effectiveness of roflumilast. Alzheimer's & Dementia. 2023;19(8):3458 [Crossref]
33- Tack P, Victor J, Gemmel P, Annemans L. Do custom 3D-printed revision acetabular implants provide enough value to justify the additional costs? The health-economic comparison of a new porous 3D-printed hip implant for revision arthroplasty of Paprosky type 3B acetabular defects and its closest alternative. Orthopaedics & Traumatology: Surgery & Research. 2021;107(1):102600 [Crossref]
34- Li J, Viceconti M, Li X, Bhattacharya P, Naimark D, Osseyran A. Cost-Effectiveness Analysis of CT-Based Finite Element Modeling for Osteoporosis Screening in Secondary Fracture Prevention: An Early Health Technology Assessment in the Netherlands. MDM Policy & Practice. 2023;8(2) [Crossref]
35- Moulaei K, Sheikhtaheri A, Nezhad M, Haghdoost A, Gheysari M, Bahaadinbeigy K. Telerehabilitation for upper limb disabilities: a scoping review on functions, outcomes, and evaluation methods. Arch Public Health. 2022;80(1) [Crossref]
36- Dakin H, Rombach I, Dritsaki M, Gray A, Ball C, Lamb S, Nanchahal J. Cost-effectiveness of adalimumab for early-stage Dupuytren’s disease. Bone & Joint Open. 2022;3(11):898 [Crossref]
37- van Prooije T, Ruigrok S, van den Berkmortel N, Maas R, Wijn S, van Roon-Mom W, van de Warrenburg B, Grutters J. The potential value of disease-modifying therapy in patients with spinocerebellar ataxia type 1: an early health economic modeling study. J Neurol. 2023;270(8):3788 [Crossref]
38- Maluleke T, Benecke R, Oladejo S, Feulner G, Kern S, Lister J, McClelland G, Njoki M, Noack P, Petruccione F, Rajaratnam K, Waitt C, Rosenkranz B, Pillai G. Cross‐disciplinary mathematical modelling to benefit healthcare – could clinical pharmacology play an enabling role?. Brit J Clinical Pharma. 2024; [Crossref]
39- Campbell H, Ratushnyak S, Georgieva A, Impey L, Rivero-Arias O. Exploring the potential cost-effectiveness of a new computerised decision support tool for identifying fetal compromise during monitored term labours: an early health economic model. Cost Eff Resour Alloc. 2024;22(1) [Crossref]
40- van Leeuwen K, Meijer F, Schalekamp S, Rutten M, van Dijk E, van Ginneken B, Govers T, de Rooij M. Cost-effectiveness of artificial intelligence aided vessel occlusion detection in acute stroke: an early health technology assessment. Insights Imaging. 2021;12(1) [Crossref]
41- Hehakaya C, Moors E, Verkooijen H, Grobbee D, Verburg F, Lam M. 177Lu-PSMA for advanced prostate cancer: are we ready to play big?. Eur J Nucl Med Mol Imaging. 2021;48(8):2325 [Crossref]
42- Dang A. Importance of Health Economics and Outcomes Research in the Product Lifecycle. Pharm Med. 2025; [Crossref]
43- Khan Z, Kidholm K, Pedersen S, Haga S, Drozd F, Sundrehagen T, Olavesen E, Halsteinli V. Developing a Program Costs Checklist of Digital Health Interventions: A Scoping Review and Empirical Case Study. PharmacoEconomics. 2024;42(6):663 [Crossref]
44- Broomhead S, Mars M, Scott R, Jones T. EHealth Investment Appraisal in Africa: A Scoping Review. INQUIRY. 2021;58 [Crossref]
45- Hedibel M, Ghanassi F, El-Fass K, Fasseeh A, Abaza S, Kaló Z. Designing a Roadmap for Health Technology Assessment Implementation in Algeria. 2024; [Crossref]
46- Drummond M, Augustovski F, Bhattacharyya D, Campbell J, Chaiyakunapruk N, Chen Y, Galindo-Suarez R, Guerino J, Mejía A, Mujoomdar M, Ollendorf D, Ronquest N, Torbica A, Tsiao E, Watkins J, Yeung K. Challenges of Health Technology Assessment in Pluralistic Healthcare Systems: An ISPOR Council Report. Value in Health. 2022;25(8):1257 [Crossref]
47- Shetty S, Walker S, Fox-Rushby J. Managing Uncomplicated Singleton Breech Pregnancy Using the OptiBreech Collaborative Care Pathway: Early Economic Model and Value of Information Analysis. Value in Health. 2025; [Crossref]
48- Kaur N, Prinja S. Health Technology Assessment in the Early Phases of Development of Medical Devices: A Catalyst for Sustainable Growth and Innovation. 2025; [Crossref]
49- Hehakaya C, van der Voort van Zyp J, Vanneste B, Grutters J, Grobbee D, Verkooijen H, Frederix G. Early health economic analysis of 1.5 T MRI-guided radiotherapy for localized prostate cancer: Decision analytic modelling. Radiotherapy and Oncology. 2021;161:74 [Crossref]
50- Otten L, Buma A, Piet B, ter Heine R, van den Heuvel M, Retèl V. Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer. PharmacoEconomics Open. 2025;9(3):471 [Crossref]
51- Al Rashdi I, Al Balushi S, Al Shuaili A, Al Rashdi S, Ibrahim Al Bulushi N, Ibrahim Al Kindi A, Al Salmi Q, Al Sabti H, Korra N, Abaza S, Fasseeh A, Kaló Z. A roadmap towards implementing health technology assessment in Oman. JHOM. 2024;38(9):241 [Crossref]
52- Teunissen F, Hehakaya C, Meijer R, van Melick H, Verkooijen H, van der Voort van Zyp J. Patient preferences for treatment modalities for localised prostate cancer. BJUI Compass. 2023;4(2):214 [Crossref]
53- Rodriguez Llorian E, Waliji L, Dragojlovic N, Michaux K, Nagase F, Lynd L. Frameworks for Health Technology Assessment at an Early Stage of Product Development: A Review and Roadmap to Guide Applications. Value in Health. 2023;26(8):1258 [Crossref]
54- Lazzaro C, van Steen C, Ghirelli G, Sacchi M, Sisto D, Uva M, Varano L, Angelillo L. A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2023;23(2):251 [Crossref]